Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VVUS: VIVUS INC. (NASDAQ) -- Ignore unavailable to you. Want to Upgrade?

To: James Baker who wrote (4457)	1/11/1998 8:52:00 PM
From: MisterED	Respond to of 23519

The following litle note in Investor's Business Daily on January 8th might shed some light on how and why some doctors defend certain drugs: <<Some 96% of the doctors who defended calcium channel blockers when the blood pressure pills were questioned in 1995 had financial relationships with pill manufact- urers, the New England Journal of Medicine reported. It said the conflicts came in the form of travel funds, speaking fees, grants, consulting contracts and educational support>>

To: James Baker who wrote (4457)	1/12/1998 12:39:00 AM
From: Tunica Albuginea	Respond to of 23519

James , Re Barrons; Re" They could not even admit that yes, it might have been more fair and accurate to have discolsed this up front. Goldstein can not give a medical lecture at a conference or publish a medical journal article without this disclosure but Barron's thinks that hidden agends just don't exist (except theri own and that is another topic!) ******************************** I think you may be asking too much from some of Barons great think tank minds. TA

To: James Baker who wrote (4457)	1/12/1998 3:51:00 AM
From: blankmind	Read Replies (2) \| Respond to of 23519

-- Barron's, I think got duped by the reporter who wrote the article trashing Vivus. -- They made the reporter respond to my letter. And the reporter maintains that Dr. Goldstein is unbiased because he works for a lot of Vivus's competitors; not just one. This is silly. Barron's and this reporter will look foolish in 2 weeks if Vivus doubles on any type of good news. -- Also, one of the doctors on here has to respond to the challenge - questioning the objectivity of Dr. Goldstein & his comments. -- Out.